Biomea Fusion, Inc. Logo

Biomea Fusion, Inc.

Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.

BMEA | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
1599 INDUSTRIAL ROAD, 94070 SAN CARLOS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oral covalent small molecules for the treatment of metabolic diseases and genetically defined cancers. The company's primary focus is on its metabolic franchise, advancing potential disease-modifying therapies for diabetes and obesity. Its lead clinical candidates include icovamenib (BMF-219), a covalent menin inhibitor being investigated for its potential to regenerate insulin-producing beta cells in patients with Type 1 and Type 2 diabetes, and BMF-650, a next-generation oral GLP-1 receptor agonist. The company's oncology pipeline features BMF-500, a covalent FLT3 inhibitor for acute leukemia. Biomea leverages its proprietary FUSION™ System to design its drug candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Biomea Fusion, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biomea Fusion, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biomea Fusion, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
Alkermes plc. Logo
Develops medicines for CNS disorders like schizophrenia, bipolar, and sleep disorders.
United States of America ALKS
Allarity Therapeutics, Inc. Logo
Develops personalized cancer drugs using a diagnostic platform to predict patient response.
United States of America ALLR
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX
Allogene Therapeutics, Inc. Logo
Developing off-the-shelf CAR T-cell therapies for cancer and autoimmune diseases.
United States of America ALLO
Israel KVSR
Almirall S.A. Logo
A global biopharmaceutical company developing innovative medical solutions for skin health.
Spain ALM
ALNYLAM PHARMACEUTICALS, INC. Logo
Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.
United States of America ALNY

Talk to a Data Expert

Have a question? We'll get back to you promptly.